Medpace (MEDP 54.51%), a clinical contract research organization that manages drug development for pharmaceutical and biotech clients, reported its second quarter 2025 earnings on July 17, 2025. The company delivered GAAP results that topped both earnings and revenue forecasts, with GAAP revenue of $603.3 million versus the estimated$538.8 million and GAAP earnings per share (EPS) of $3.10 versus the expected$2.98. The period's robust GAAP figures outpaced analyst estimates. Overall, the quarter featured ...